Latrunculin B
Based on 6 publication(s) in Google Scholar
Latrunculin B, an antimicrobial marine alkaloid, is an actin polymerization inhibitor. Latrunculin B regulates pulmonary vein electrophysiological characteristics and attenuates stretch-induced arrhythmogenesis. Antifungal and antiprotozoal activity.
For research use only. We do not sell to patients.
- Purity: 98.95%
- CAS No.: 76343-94-7
- Formula: C20H29NO5S
- Molecular Weight:395.51
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Latrunculin B
More
Customer Validation & Images
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
WB
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
7.1 μM
Compound: 2, NSC-339663
|
Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay
Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay
|
[PMID: 18942825] |
| HepG2 | IC50 |
19.27 μM
Compound: 99b
|
Anticancer activity against human HepG2 cells assessed as inhibition of cell growth
Anticancer activity against human HepG2 cells assessed as inhibition of cell growth
|
[PMID: 33940466] |
| HUVEC | IC50 |
478 nM
Compound: LatB
|
Inhibition of cell migration in human HUVEC cells assessed as decrease in cell velocity measured after 16 hrs by crystal violet staining based scratch assay
Inhibition of cell migration in human HUVEC cells assessed as decrease in cell velocity measured after 16 hrs by crystal violet staining based scratch assay
|
[PMID: 31260301] |
| HUVEC | IC50 |
611.6 nM
Compound: LatB
|
Antiproliferative activity against human HUVEC measured after 72 hrs
Antiproliferative activity against human HUVEC measured after 72 hrs
|
[PMID: 31260301] |
| MDA-MB-435 | IC50 |
4.8 μM
Compound: 2, NSC-339663
|
Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay
|
[PMID: 18942825] |
Latrunculin B displays growth inhibition of HeLa cells with an IC50 value of 1.4 μM[1].
Latrunculin B modulates electrophysiological characteristics and arrhythmogenesis in pulmonary vein cardiomyocytes. Latrunculin B (100 nM) decreases the spontaneous electrical activity by 16±4% in pulmonary vein (PV) preparations. Latrunculin B (100 nM) decreases the late Na+ current, L-type Ca2+ current, Na+/Ca2+ exchanger current, and stretch-activated BKCa current in PV cardiomyocytes. Latrunculin B reduces the transient outward K+ current and ultra-rapid delayed rectifier K+ current, but increases the delayed rectifier K+ current in isolated PV cardiomyocytes. Latrunculin B (100 nM) decreases intracellular Ca2+ transient and sarcoplasmic reticulum Ca2+ content in PV cardiomyocytes. Latrunculin B attenuates stretch-induced increased spontaneous electrical activity and trigger activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 76343-94-7
-
Appearance Solid
-
Molecular Weight 395.51
-
Formula C20H29NO5S
-
Color Colorless to off-white
-
SMILES
O=C1SC[C@@H]([C@]2(O)O[C@]3([H])CC[C@H](C)/C=C\CC/C(C)=C\C(O[C@@](C3)([H])C2)=O)N1
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Topology Outweighs Stiffness: Self-Reinforced Cell Mechanotransduction via Multiaxial Curvature Engineering of Ultrasoft Hydrogels. [Abstract]2026 Mar 10;20(9):7679-7692. PMID: 41733433
Latrunculin B purchased from MedChemExpress. Usage Cited in: ACS Nano. 2026 Mar 10;20(9):7679-7692. [Abstract]
Expression of Lamin A/C when hMSCs were treated with 20 μM Blebbistatin and 0.2 μM Latrunculin B adhering to C100, C70 and FLAT hydrogels. (a) The fluorescent images and (b) the quantification of Lamin A/C; the insets show the wrinkle generation on the nucleus after Blebbistatin and Latrunculin B treatment.
Latrunculin B purchased from MedChemExpress. Usage Cited in: ACS Nano. 2026 Mar 10;20(9):7679-7692. [Abstract]
Actin of hMSCs treated 0.2 μM Latrunculin B. (a) The fluorescent images and (b) the schematic illustration of expressed actin indicate Latrunculin B treatment inhibits actin fiber formation.
Latrunculin B purchased from MedChemExpress. Usage Cited in: ACS Nano. 2026 Mar 10;20(9):7679-7692. [Abstract]
The fluorescent images and surface area of hMSCs treated with 0.2 μM Latrunculin B.
-
ACS Nano
Programmed Cell Death Protein 1 Engagement Impairs Cytoskeletal Forces and Nuclear Mechanotransduction in T Cells. [Abstract]2025 Nov 25;19(46):39667-39681. PMID: 41221724 -
Nat Commun
2025 Jul 18;16(1):6621. PMID: 40681515
Latrunculin B purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]
Latrunculin B (10 μM; pre-incubated for 10 min and then added with 20 μM monensin for 1 h) did not affect the formation of monensin-induced ATG8-positive invaginated vesicles in vacuoles.
-
Adv Sci (Weinh)
ERAD Component MoHrd3 Facilitates Pathogenicity and Establishes a Direct Regulation on Autophagy in Magnaporthe Oryzae. [Abstract]2026 Apr;13(24):e20627. PMID: 41725610 -
Adv Sci (Weinh)
Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant Glioblastoma. [Abstract]2025 Dec 27:e13632. PMID: 41454694
Latrunculin B purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 27:e13632. [Abstract]
Latrunculin B (1 μM; 30 min) inhibited nuclear actin polymerization in TMZresistant GBM cells.
Latrunculin B purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 27:e13632. [Abstract]
Latrunculin B (1 μM; 30 min) significantly reduced the formation of nuclear F-actin in TMZ-resistant GBM cells compared to the DMSO-treated group. Immunofluorescence analysis of TMZ‐resistant GBM cells treated with Lifeact‐EGFP‐2xNLS plasmids after DMSO or LatB treatment.
Latrunculin B purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 27:e13632. [Abstract]
Latrunculin B (1 μM; 24 h) increased apoptosis in TMZ-resistant GBM cells treated with both TMZ and LatB.
-
Int J Mol Sci
2025 Apr 18;26(8):3864. PMID: 40332566
Solvent & Solubility
DMSO : 25 mg/mL (63.21 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Diaa T A Youssef, et al. Magnificines A and B, Antimicrobial Marine Alkaloids Featuring a Tetrahydrooxazolo[3,2-a]azepine-2,5( 3H,6H)-dione Backbone from the Red Sea Sponge Negombata magnifica. Mar Drugs. 2021 Apr 12;19(4):214. [Content Brief]
[2]. Yen-Yu Lu, et al. Latrunculin B modulates electrophysiological characteristics and arrhythmogenesis in pulmonary vein cardiomyocytes. Clin Sci (Lond). 2016 May;130(9):721-32. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5284 mL | 12.6419 mL | 25.2838 mL | 63.2095 mL |
| 5 mM | 0.5057 mL | 2.5284 mL | 5.0568 mL | 12.6419 mL | |
| 10 mM | 0.2528 mL | 1.2642 mL | 2.5284 mL | 6.3210 mL | |
| 15 mM | 0.1686 mL | 0.8428 mL | 1.6856 mL | 4.2140 mL | |
| 20 mM | 0.1264 mL | 0.6321 mL | 1.2642 mL | 3.1605 mL | |
| 25 mM | 0.1011 mL | 0.5057 mL | 1.0114 mL | 2.5284 mL | |
| 30 mM | 0.0843 mL | 0.4214 mL | 0.8428 mL | 2.1070 mL | |
| 40 mM | 0.0632 mL | 0.3160 mL | 0.6321 mL | 1.5802 mL | |
| 50 mM | 0.0506 mL | 0.2528 mL | 0.5057 mL | 1.2642 mL | |
| 60 mM | 0.0421 mL | 0.2107 mL | 0.4214 mL | 1.0535 mL |
Latrunculin B Related Classifications
HY-101848 Related Classifications
Powered by Bioz